Compare KRRO & OCCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRRO | OCCI |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.0M | 120.2M |
| IPO Year | 2019 | N/A |
| Metric | KRRO | OCCI |
|---|---|---|
| Price | $11.85 | $2.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $47.10 | N/A |
| AVG Volume (30 Days) | 150.3K | ★ 578.9K |
| Earning Date | 06-17-2026 | 12-11-2023 |
| Dividend Yield | N/A | ★ 24.32% |
| EPS Growth | ★ 82.35 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,271,000.00 | N/A |
| Revenue This Year | $145.97 | N/A |
| Revenue Next Year | N/A | $10.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.20 | $2.79 |
| 52 Week High | $55.89 | $7.17 |
| Indicator | KRRO | OCCI |
|---|---|---|
| Relative Strength Index (RSI) | 52.87 | 30.46 |
| Support Level | $10.55 | $2.83 |
| Resistance Level | $12.54 | $4.97 |
| Average True Range (ATR) | 0.81 | 0.14 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 56.73 | 35.03 |
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation through investment in collateralized loan obligation (CLO) equity and debt securities. The company invests in floating rate credit instruments and other structured credit investments, including collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.